Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

By K. Blackwell, H. Burstein, A. Storniolo, H. Rugo, G. Sledge, M. Koehler, C. Ellis, M. Casey, S. Vukelja, J. Bischoff and 2 more. Journal of Clinical Oncology, 2010

977 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/d2e57b189b240c45008a591b127cfa06b81dac5f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Carlos L. Arteaga
2. A. Lluch

In Oncology

1. Carlos L. Arteaga
2. J. Engelman
3. M. Sliwkowski
4. L. Gianni
5. M. Lacouture

Citations in the corpus

• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “97) 4 [95, 96]”
• Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, background): “This set researchers to investigate the possibilities of dual targeting of the HER-2 receptor.(60) The Neo-ALTTO trial(32) proved that a dual inhibition achieves a greater rate of pCR.”
• Antibodies and cancer therapy: versatile platforms for cancer immunotherapy (2010, background): “A recent Phase III clinical trial showed that trastuzumab and lapatinib combination therapy improved progression-free survival compared with lapatinib monotherapy in patients with HER2-positive, trastuzumab-refractory metastatic breast cance”
• ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “For example, the combination of trastuzumab and lapatinib is superior to each agent alone in both the metastatic (Blackwell et al., 2010) and neoadjuvant (Baselga et al.”
• Treatment of HER2-positive breast cancer: current status and future perspectives (2012, background): “A subsequent randomized trial also showed that the combination of lapatinib and trastuzumab had better efficacy than lapatinib alone in patients whose disease had progressed on trastuzumab”